Medical emergency?Emergency? Call 911. Nearest emergency roomsNearest ERs

Prescription medicine · generic available

Imipenem and cilastatin sodium

Also listed by the FDA as: cilastatin sodium / imipenem · cilastatin sodium / imipenem anhydrous

Drug class: Penem Antibacterial

The FDA’s “Established Pharmacologic Class”: the group of medicines that work in a similar way.

Official FDA data, not advice

Everything here comes from the U.S. Food and Drug Administration (FDA): the drug label, the NDC Directory, Drugs@FDA, recall reports and the drug shortage list. Each fact shows its source and date.

This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or change any medicine.

In an emergency, call 911. If someone may have taken too much of a medicine, call Poison Help: 1‑800‑222‑1222.

Imipenem and cilastatin sodium key facts

Drug class
Penem Antibacterial
Used for
Imipenem and Cilastatin for Injection, USP for intravenous use is a combination of imipenem, a penem antibacterial, and cilastatin, a renal dehydropeptidase inhibitor, indicated for the treatment of the following serious infections caused by designated susceptible bacteria … (source)
Prescription or over the counter
Prescription (Rx)
Generic available
Yes
Latest FDA recall
None listed

Sources: FDA label (October 11, 2022); FDA NDC Directory (October 30, 2026); FDA enforcement reports (October 27, 2026). Not medical advice.

Quick answers

What is Imipenem and cilastatin sodium used for?
The FDA-approved label (Imipenem and Cilastatin, Fresenius Kabi USA, LLC, October 11, 2022) says: “Imipenem and Cilastatin for Injection, USP for intravenous use is a combination of imipenem, a penem antibacterial, and cilastatin, a renal dehydropeptidase inhibitor, indicated for the treatment of the following serious infections caused by designated susceptible bacteria: Lower respiratory tract infections. Urinary tract infections. Intra-abdominal infections. Gynecologic infections. Bacterial septicemia. …” This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or change any medicine.
What are the side effects of Imipenem and cilastatin sodium?
The “Adverse Reactions” section of the FDA label (Imipenem and Cilastatin, Fresenius Kabi USA, LLC, October 11, 2022) begins: “The following serious adverse reactions are described in greater detail in the Warnings and Precautions section.” … This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or change any medicine.
What are the drug interactions of Imipenem and cilastatin sodium?
The “Drug Interactions” section of the FDA label (Imipenem and Cilastatin, Fresenius Kabi USA, LLC, October 11, 2022) begins: “Ganciclovir: Generalized seizures have been reported in patients who received ganciclovir. Do not co-administer unless benefit outweighs risk (7.1). Probenecid: Concomitant administration of Imipenem and Cilastatin for Injection (I.V.) and probenecid results in increases in the plasma level and half-life of imipenem. Concomitant administration is not recommended (7.2).” … This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or change any medicine.
Does Imipenem and cilastatin sodium have a boxed warning?
No. None of the 4 FDA labels we found for this medicine has a boxed warning.
Is there a shortage of Imipenem and cilastatin sodium?
The FDA drug shortage list shows “To be discontinued” for a product of this medicine (updated January 8, 2026). Ask your pharmacist about alternatives.
Has Imipenem and cilastatin sodium been recalled?
No recall linked to the products of this medicine appears in the FDA enforcement reports we use.
Who makes Imipenem and cilastatin sodium?
3 companies list prescription products of Imipenem and cilastatin sodium in the FDA NDC Directory, including Fresenius Kabi USA, LLC, Merck Sharp & Dohme LLC and WG Critical Care, LLC.

What Imipenem and cilastatin sodium is used for

Quoted from the “Indications and Usage” section of the FDA-approved label.

Imipenem and Cilastatin for Injection, USP for intravenous use is a combination of imipenem, a penem antibacterial, and cilastatin, a renal dehydropeptidase inhibitor, indicated for the treatment of the following serious infections caused by designated susceptible bacteria: Lower respiratory tract infections. Urinary tract infections. Intra-abdominal infections. Gynecologic infections. Bacterial septicemia. …

— FDA label: Imipenem and Cilastatin, Fresenius Kabi USA, LLC, effective October 11, 2022. Read the full label on DailyMed →

Label quoted: the one for the most common form (injection, powder, for solution, intravenous), Imipenem and Cilastatin, Fresenius Kabi USA, LLC; it covers 2 products in the FDA NDC Directory. The side effects, interactions, dosage and pregnancy quotes below come from this same label.

The FDA has 4 labels for products of this medicine (different makers and forms); uses can differ between them. Check the label that comes with your own medicine.

This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or change any medicine.

Conditions named on the label

These condition names appear word for word in the label’s “Indications and Usage” text (matched with a reviewed table). Each page lists hospitals whose own websites name the condition.

Related medical specialties

Boxed warning

A boxed warning (“black box”) is the FDA’s strongest warning on a drug label, for serious or life-threatening risks.

The label quoted above has no boxed warning.

0 of 4 FDA labels for this medicine have a boxed warning.

Imipenem and cilastatin sodium side effects

Quoted from the “Adverse Reactions” section of the FDA-approved label. Tell your doctor about any side effect that worries you.

The following serious adverse reactions are described in greater detail in the Warnings and Precautions section.

Read more of this section

Hypersensitivity Reactions [see Warnings and Precautions (5.1)] Seizure Potential [see Warnings and Precautions (5.2)] Increased Seizure Potential Due to Interaction with Valproic Acid [see Warnings and Precautions (5.3)] Clostridioides difficile -Associated Diarrhea (CDAD) [see Warnings and Precautions (5.4)] Development of Drug-Resistant Bacteria [see Warnings and Precautions (5.5)] The most frequently occurring adverse reactions (≥ 0.2%) in adults were phlebitis, nausea, diarrhea, vomiting, rash, pain injection site, fever, hypotension, seizures, erythema at injection site, dizziness, pruritus, vein induration, urticaria, somnolence (6.1). The most frequently occurring adverse reactions (> 1%) in pediatric patients greater than or equal to 3 months of age were diarrhea, rash, phlebitis, gastroenteritis, vomiting, IV site irritation, urine discoloration (6.1). The most frequently occurring adverse reactions (> 1%) in neonates to 3 months of age were convulsions, diarrhea, oliguria/anuria, oral candidiasis, rash, tachycardia (6.1). To report SUSPECTED ADVERSE REACTIONS, contact Fresenius Kabi USA, LLC at 1-800-551-7176 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. Adult Patients During clinical investigations 1,723 patients were treated with Imipenem and Cilastatin for Injection (I.V.). Table 4 shows the incidence of adverse reactions reported during the clinical investigations of adult patients treated with Imipenem and Cilastatin for Injection (I.V.). Table 4: Incidence (%)* of Adverse Reactions Reported During Clinical Investigations of Adult Patients Treated with Imipenem and Cilastatin for Injection (I.V.) * Adverse reactions with an incidence ≥ 0.2% of Imipenem and Cilastatin for Injection (I.V.) -treated adult patients. Body System Adverse Reactions Frequency (%) Local Administration site Phlebitis/ thrombophlebitis 3.1% Pain at the injection site 0.7% Erythema at the injection site 0.4% Vein induration 0.2% Gastrointestinal Nausea 2% Diarrhea 1.8% Vomiting 1.5% Skin Rash 0.9% Pruritus 0.3% Urticaria 0.2% Vascular Hypotension 0.4% Body as a Whole Fever 0.5% Nervous system Seizures 0.4% Dizziness 0.3% Somnolence 0.2% Additional adverse reactions reported in less than 0.2% of the patients or reported since the drug was marketed are listed within each body system in order of decreasing severity [see Table 5].

— FDA label: Imipenem and Cilastatin, Fresenius Kabi USA, LLC, effective October 11, 2022. This is part of the section. Read the full label on DailyMed →

Imipenem and cilastatin sodium drug interactions

Quoted from the “Drug Interactions” section of the FDA-approved label. Tell your pharmacist about every medicine, vitamin and herbal product you take.

Ganciclovir: Generalized seizures have been reported in patients who received ganciclovir. Do not co-administer unless benefit outweighs risk (7.1). Probenecid: Concomitant administration of Imipenem and Cilastatin for Injection (I.V.) and probenecid results in increases in the plasma level and half-life of imipenem. Concomitant administration is not recommended (7.2).

Read more of this section

Valproic acid/divalproex sodium: Concomitant use with Imipenem and Cilastatin for Injection (I.V.) is generally not recommended. Consider other antibacterial drugs to treat infections in patients whose seizures are well-controlled on valproic acid or divalproex sodium (5.3, 7.3). 7.1 Ganciclovir Generalized seizures have been reported in patients who received ganciclovir and Imipenem and Cilastatin for Injection (I.V.). These drugs should not be used concomitantly with Imipenem and Cilastatin for Injection (I.V.) unless the potential benefits outweigh the risks. 7.2 Probenecid Concomitant administration of Imipenem and Cilastatin for Injection (I.V.) and probenecid results in increases in the plasma level and half-life of imipenem. Therefore, it is not recommended that probenecid be given concomitantly with Imipenem and Cilastatin for Injection (I.V.). 7.3 Valproic Acid Case reports in the literature have shown that co-administration of carbapenems, including Imipenem and Cilastatin for Injection (I.V.), to patients receiving valproic acid or divalproex sodium results in a reduction in valproic acid concentrations. The valproic acid concentrations may drop below the therapeutic range as a result of this interaction, therefore increasing the risk of breakthrough seizures. Although the mechanism of this interaction is unknown, data from in vitro and animal studies suggest that carbapenems may inhibit the hydrolysis of valproic acid's glucuronide metabolite (VPA-g) back to valproic acid, thus decreasing the serum concentrations of valproic acid [see Warnings and Precautions (5.3)]. The concomitant use of Imipenem and Cilastatin for Injection (I.V.) and valproic acid/divalproex sodium is generally not recommended. Antibacterials other than carbapenems should be considered to treat infections in patients whose seizures are well-controlled on valproic acid or divalproex sodium.

— FDA label: Imipenem and Cilastatin, Fresenius Kabi USA, LLC, effective October 11, 2022. Read the full label on DailyMed →

Imipenem and cilastatin sodium dosage

Quoted from the “Dosage and Administration” section of the FDA-approved label. Your own dose is the one your doctor prescribes: do not change it on your own.

The dosage of Imipenem and Cilastatin for Injection (I.V.) in adult patients should be based on suspected or confirmed pathogen susceptibility (2.1). For adult patients with normal renal function (creatinine clearance of greater than or equal to 90 mL/min), the recommended dosage regimens are: 500 mg every 6 hours OR 1,000 mg every 8 hours OR 1,000 mg every 6 hours (2.1). See full prescribing information for dosage recommendations in pediatric patients (2.2).

Read more of this section

A reduction in dose must be made for a patient with a creatinine clearance of less than 90 mL/min (2.3). Patients with creatinine clearances of less than 15 mL/min should not receive Imipenem and Cilastatin for Injection (I.V.) unless hemodialysis is instituted within 48 hours (2.4). Reconstitute Imipenem and Cilastatin for Injection, USP (I.V.) vial with appropriate diluent and dilute the reconstituted suspension with an appropriate infusion solution before administering by intravenous infusion (2.5). 2.1 Dosage in Adults For Intravenous Injection Only The dosage of Imipenem and Cilastatin for Injection (I.V.) in adult patients should be based on suspected or confirmed pathogen susceptibility as shown in Table 1 below. The dosage recommendations for Imipenem and Cilastatin for Injection (I.V.) represent the quantity of imipenem to be administered. An equivalent amount of cilastatin is also present in the solution. These doses should be used for patients with creatinine clearance of greater than or equal to 90 mL/min. A reduction in dose must be made for patients with creatinine clearance less than 90 mL/min as shown in Table 3 [see Dosage and Administration (2.3)]. Recommend that the maximum total daily dosage not exceed 4 g/day. Administer 500 mg by intravenous infusion over 20 to 30 minutes. Administer 1,000 mg by intravenous infusion over 40 to 60 minutes. In patients who develop nausea during the infusion, the rate of infusion may be slowed. Table 1: Dosage of Imipenem and Cilastatin for Injection (I.V.) in Adult Patients with Creatinine Clearance Greater than or Equal to 90 mL/min Suspected or Proven Pathogen Susceptibility Dosage of Imipenem and Cilastatin for Injection (I.V.) If the infection is suspected or proven to be due to a susceptible bacterial species 500 mg every 6 hours OR 1,000 mg every 8 hours If the infection is suspected or proven to be due to bacterial species with intermediate susceptibility [see Microbiology (12.4)] 1,000 mg every 6 hours 2.2 Dosage in Pediatric Patients Imipenem and Cilastatin for Injection (I.V.) is not recommended in pediatric patients with CNS infections because of the risk of seizures [see Use in Specific Populations (8.4)]. Imipenem and Cilastatin for Injection (I.V.) is not recommended in pediatric patients < 30 kg with renal impairment, as no data are available [see Use in Specific Populations (8.4)]. Based on studies in adults, the maximum total daily dose in pediatric patients should not exceed 4 g/day [see Dosage and Administration (2.1)].

Table from the label
Suspected or Proven Pathogen SusceptibilityDosage of Imipenem and Cilastatin for Injection (I.V.)
If the infection is suspected or proven to be due to a susceptible bacterial species500 mg every 6 hours OR 1,000 mg every 8 hours
If the infection is suspected or proven to be due to bacterial species with intermediate susceptibility [see Microbiology ( 12.4)]1,000 mg every 6 hours

— FDA label: Imipenem and Cilastatin, Fresenius Kabi USA, LLC, effective October 11, 2022. This is part of the section. Read the full label on DailyMed →

Imipenem and cilastatin sodium in pregnancy

Quoted from the pregnancy part of the FDA-approved label. Ask your doctor before you take any medicine while pregnant or planning a pregnancy.

Risk Summary Available data from a small number of postmarketing cases with Imipenem and Cilastatin for Injection (I.V.) use in pregnancy are not sufficient to identify any drug-associated risks for major birth defects, miscarriage, or adverse maternal or fetal outcomes.

Read more of this section

Developmental toxicity studies with imipenem and cilastatin sodium (alone or in combination) administered to mice, rats, rabbits, and monkeys at doses 0.4 to 2.9 times the recommended human dose (RHD), (based on body surface area), showed no drug-induced fetal malformations. Embryofetal development studies with imipenem/cilastatin administered to cynomolgus monkeys at doses similar to the RHD (based on body surface area) showed an increase in embryonic loss (see Data). The background risk of major birth defects and miscarriage for the indicated populations is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. The background risk of major birth defects is 2-4% and of miscarriage is 15-20% of clinically recognized pregnancies within the general population. Data Animal Data Reproductive toxicity studies with imipenem and cilastatin (alone or in combination) administered to mice, rats, and rabbits showed no evidence of effects on embryofetal (mice, rats and rabbits) or pre/postnatal (rats) development. Imipenem was administered intravenously to rats (gestation days (GD) 7 to 17) and rabbits (GD 6 to 18) at doses up to 900 and 60 mg/kg/day, respectively, approximately 2.9 and 0.4 times the RHD (based on body surface area). Cilastatin was administered subcutaneously to rats (GD 6 to 17) and intravenously to rabbits (GD 6 to 18) at doses up to 1000 and 300 mg/kg/day, respectively, approximately 3.2 and 1.9 times the RHD (based on body surface area). Imipenem/cilastatin was administered intravenously to mice at doses up to 320 mg/kg/day (GD 6 to 15). In two separate studies, imipenem/cilastatin was administered to rats (GD 6 to 17 and GD 15 to day 21 postpartum) both intravenously at doses up to 80 mg/kg/day and subcutaneously at 320 mg/kg/day. The higher dose is approximately equal to the RHD (based on body surface area). Imipenem/cilastatin administered intravenously to pregnant cynomolgus monkeys during organogenesis at 100 mg/kg/day, approximately 0.6 times the RHD (based on body surface area), at an infusion rate mimicking human clinical use, was not associated with fetal malformations, but there was an increase in embryonic loss relative to controls. Imipenem/cilastatin administered to pregnant cynomolgus monkeys during organogenesis at 40 mg/kg/day by bolus intravenous injection caused significant maternal toxicity including death and embryofetal loss.

— FDA label: Imipenem and Cilastatin, Fresenius Kabi USA, LLC, effective October 11, 2022. Read the full label on DailyMed →

When Imipenem and cilastatin sodium should not be used

Quoted from the “Contraindications” section of the FDA-approved label.

Imipenem and Cilastatin for Injection (I.V.) is contraindicated in patients who have shown hypersensitivity to any component of this product. Known hypersensitivity to any component of Imipenem and Cilastatin for Injection (I.V.) (4)

— FDA label: Imipenem and Cilastatin, Fresenius Kabi USA, LLC, effective October 11, 2022. Read the full label on DailyMed →

Imipenem and cilastatin sodium overdose

Quoted from the “Overdosage” section of the FDA-approved label. If someone may have taken too much, call Poison Help at 1-800-222-1222 (or 911 in an emergency).

In the case of overdosage, discontinue Imipenem and Cilastatin for Injection (I.V.), treat symptomatically, and institute supportive measures as required. Imipenem and Cilastatin for Injection (I.V.) is hemodialyzable.

— FDA label: Imipenem and Cilastatin, Fresenius Kabi USA, LLC, effective October 11, 2022. Read the full label on DailyMed →

Forms and how it is given

Dosage formsInjection, powder, for solution
RouteIntravenous
Prescription products4 in the FDA NDC Directory
Brand namesPrimaxin IV

Companies that list this medicine

Labelers in the FDA NDC Directory: the company named on the package (maker or distributor), with the number of prescription products.

FDA approval history

  • NDA: New Drug Application: how a new (usually brand-name) medicine is approved.
  • ANDA: Abbreviated New Drug Application: how a generic version is approved.
Brand and biologic applications
ApplicationSponsorApprovedLater changes approved
NDA050587
PRIMAXIN
MerckNovember 26, 1985 51, latest January 30, 2022
2022: Labeling · 2018: Labeling · 2018: Manufacturing (CMC)

Generic approvals (2)

Shortage status

To be discontinued · updated January 8, 2026 · first posted January 8, 2026

ProductPrimaxin, Injection, 500mg (NDC 0006-3516-59)
CompanyMerck Sharp & Dohme Corp.

Ask your pharmacist whether your product is affected and what the options are.

FDA Drug Shortages database →

Recalls

No recall linked to these products (by their NDC code) appears in the FDA enforcement reports.

Official identifiers

RxCUI (RxNorm)1726204, 1726214
SPL set ID of the quoted labelce771566-c4f2-447e-944a-6b908925c90b
FDA labels (SPL)4
FDA applicationsNDA050587, 2 ANDA
Active ingredients (FDA)CILASTATIN / IMIPENEM

Next steps

Sources

  1. FDA-approved label on DailyMed (National Library of Medicine) — Imipenem and Cilastatin, Fresenius Kabi USA, LLC, effective October 11, 2022; via openFDA, FDA data exported October 30, 2026, retrieved October 31, 2026
  2. NDC Directory (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026
  3. Drugs@FDA (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026
  4. Drug recall enforcement reports (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 27, 2026, retrieved October 31, 2026
  5. Drug shortages (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026

openFDA data is provided by the FDA as is; it may be incomplete. Always rely on the label that comes with your medicine. FDA Enforcement Report search →

Report an error → · Information for medicine makers